Zogenix to Present at UBS 2011 Global Life Sciences Conference
SAN DIEGO, Sep 19, 2011 (GlobeNewswire via COMTEX) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Stephen J. Farr, Ph.D., President and Chief Operating Officer, and Ann Rhoads, Executive Vice President and Chief Financial Officer, will be presenting at the UBS 2011 Global Life Sciences Conference on September 21, 2011 at the Grand Hyatt hotel in New York, NY.
Dr. Farr and Ms. Rhoads will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
UBS 2011 Global Life Sciences Event: Conference Date: Wednesday, September 21, 2011 Time: 7:30 AM ET Place: Ballroom IV, Grand Hyatt New York
The presentation will be webcast live and archived for 90 days on Zogenix' Investor Relations website at ir.zogenix.com.
Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead product candidate, Zohydro(TM) (hydrocodone bitartrate), is a novel, oral, single-entity (without acetaminophen) extended-release capsule formulation currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix's second DosePro product candidate, Relday(TM), is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia.
This news release was distributed by GlobeNewswire, www.globenewswire.com